Harrow (NASDAQ:HROW) Given New $26.00 Price Target at Craig Hallum

Harrow (NASDAQ:HROW - Free Report) had its target price lifted by Craig Hallum from $24.00 to $26.00 in a research report sent to investors on Wednesday morning, Benzinga reports. Craig Hallum currently has a buy rating on the stock.

Separately, B. Riley reissued a buy rating and set a $29.00 target price (up previously from $26.00) on shares of Harrow in a report on Wednesday.

Harrow Stock Performance

NASDAQ HROW traded down $0.31 on Wednesday, hitting $15.93. 1,013,789 shares of the stock traded hands, compared to its average volume of 471,957. The company has a debt-to-equity ratio of 2.60, a quick ratio of 2.61 and a current ratio of 2.83. The business's fifty day moving average is $11.64 and its two-hundred day moving average is $10.92. Harrow has a 12 month low of $7.60 and a 12 month high of $24.19. The firm has a market capitalization of $563.46 million, a price-to-earnings ratio of -17.50 and a beta of 0.58.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings data on Tuesday, March 19th. The company reported ($0.27) earnings per share for the quarter. The firm had revenue of $36.36 million during the quarter, compared to analysts' expectations of $37.65 million. Harrow had a negative return on equity of 40.58% and a negative net margin of 22.59%. As a group, equities analysts anticipate that Harrow will post -0.39 EPS for the current fiscal year.

Insider Buying and Selling at Harrow

In other Harrow news, major shareholder Opaleye Management Inc. acquired 50,600 shares of the stock in a transaction that occurred on Wednesday, March 20th. The shares were bought at an average price of $9.65 per share, for a total transaction of $488,290.00. Following the completion of the transaction, the insider now owns 3,695,600 shares of the company's stock, valued at approximately $35,662,540. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Mark L. Baum purchased 9,000 shares of the firm's stock in a transaction dated Friday, March 22nd. The shares were purchased at an average price of $11.59 per share, with a total value of $104,310.00. Following the acquisition, the chief executive officer now directly owns 2,137,525 shares of the company's stock, valued at $24,773,914.75. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Opaleye Management Inc. acquired 50,600 shares of the stock in a transaction dated Wednesday, March 20th. The shares were bought at an average price of $9.65 per share, for a total transaction of $488,290.00. Following the transaction, the insider now owns 3,695,600 shares in the company, valued at approximately $35,662,540. The disclosure for this purchase can be found here. Insiders bought a total of 170,715 shares of company stock valued at $1,864,011 in the last three months. Company insiders own 13.60% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its holdings in shares of Harrow by 6.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 16,672 shares of the company's stock worth $221,000 after purchasing an additional 1,033 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in Harrow in the third quarter worth approximately $26,000. BNP Paribas Financial Markets grew its position in Harrow by 12.7% during the first quarter. BNP Paribas Financial Markets now owns 16,941 shares of the company's stock valued at $224,000 after acquiring an additional 1,912 shares during the last quarter. Equitable Trust Co. raised its stake in shares of Harrow by 2.9% during the first quarter. Equitable Trust Co. now owns 83,500 shares of the company's stock worth $1,105,000 after acquiring an additional 2,345 shares in the last quarter. Finally, Stonehage Fleming Financial Services Holdings Ltd bought a new stake in shares of Harrow in the 3rd quarter worth approximately $34,000. Institutional investors own 72.76% of the company's stock.

Harrow Company Profile

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.